Traders Blog - Analysis, Strategies, News and more | Category - Analysis

Ethereum Bug Raises Red Flags
Analysis

Ethereum Bug Raises Red Flags

Ethereum, the second-largest cryptocurrency, faces a serious software flaw that could split the network in two and damage the broader crypto market. This is not just a technical hiccup, it`s a major worry for investors and a test for the entire block...

Author:
Mary Wild
Published on: 23.01.2024 17:39 (UTC)
3477
Why choose IFC Markets CFD Forex Broker
Analysis

Why choose IFC Markets CFD Forex Broker

IFC Markets is a leading international online broker offering a wide range of trading instruments, including forex, stocks, indices, and commodities. The company was founded in 2006 and is regulated by the BVI Financial Services Commission. IFC Marke...

Author:
Mary Wild
Published on: 08.01.2024 17:37 (UTC)
2684
Energy Stocks Face Headwinds in 2024: Analysts Predict Price Downturn
Analysis

Energy Stocks Face Headwinds in 2024: Analysts Predict Price Downturn

The energy sector is bracing for a potentially turbulent 2024, with analysts forecasting a significant decline in oil prices and a subsequent slump in energy stock performance.Rising Spare Capacity Threatens Oil PricesThe primary driver of this beari...

Author:
Mary Wild
Published on: 06.12.2023 15:05 (UTC)
1284
Gold Rally Might Be Getting Ahead of Itself
Analysis

Gold Rally Might Be Getting Ahead of Itself

The recent surge in gold prices has been nothing short of spectacular, driven by a confluence of positive factors. Real yields, which have a strong negative correlation with gold, have been on a downward trajectory thanks to softening US economic dat...

Author:
Mary Wild
Published on: 04.12.2023 15:26 (UTC)
1811
AbbVie's Big Buy of ImmunoGen Opens Doors for Potential Investment Gains
Analysis

AbbVie's Big Buy of ImmunoGen Opens Doors for Potential Investment Gains

In some major news dropped on Thursday, AbbVie, the big pharmaceutical player, has announced plans to snatch up ImmunoGen, a drugmaker, for a whopping $10.1 billion. This move is a game-changer for AbbVie, as it brings a promising ovarian cancer drug...

Author:
Mary Wild
Published on: 30.11.2023 18:12 (UTC)
1040

Subscription

Subscribe to receive our latest news on your email.

Subscribe to receive our latest news on your email.